JSPR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Jasper Therapeutics Inc (JSPR) is not a strong buy for a beginner investor with a long-term strategy at this moment. The technical indicators suggest a bearish trend, and the financial performance shows no significant growth. While hedge funds are buying, the lack of strong positive catalysts, weak options sentiment, and neutral analyst ratings make this stock a hold rather than a buy.
The technical indicators are bearish: MACD is negatively expanding (-0.0139), RSI is neutral (24.45), and moving averages show a bearish alignment (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 1.098), but there is no clear upward momentum.
Hedge funds are significantly increasing their positions, with a 364.54% increase in buying over the last quarter.
The company has no revenue growth, negative net income, and declining EPS (-8.87% YoY). Analyst coverage is neutral with no strong buy recommendations. Technical indicators are bearish, and options sentiment is weak with low call volume.
In Q3 2025, the company reported no revenue growth (0% YoY), a slight improvement in net income (-$18.74M, up 0.53% YoY), and a decline in EPS (-1.13, down -8.87% YoY). Gross margin remains at 0%.
UBS initiated coverage with a Neutral rating and a $1.50 price target, citing balanced risk-reward and competitive uncertainties. No strong buy recommendations are present.
